Cinclus Pharma

16.94 SEK

-3.42 %

Less than 1K followers

CINPHA

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

-3.42 %

-7.83 %

-12.05 %

-2.64 %

+5.48 %

+5.90 %

-

-

-48.04 %

Cinclus Pharma is a Swedish clinical-stage pharmaceutical company. The company is active in the development of molecules for the treatment of acid-related diseases. The company's lead drug candidate linaprazan glurate is being developed for the treatment of severe gastroesophageal reflux disease (GERD). Cinclus Pharma was founded in 2014 and is headquartered in Stockholm, Sweden.

Market cap

802.82M SEK

Turnover

1.92M SEK

Revenue

57.47M

EBIT %

-347.24 %

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

13.5

2026

Interim report Q1'26

21.5

2026

General meeting '26

19.8

2026

Interim report Q2'26

All

Webcasts

Press releases

ShowingAll content types

Press release19 hours ago

Cinclus Pharma: FDA Determines That a Single Pivotal Study Is the New Standard for Market Approval in the US – Positive for the Company’s Phase III Program

Press release2/18/2026, 11:31 AM

Redeye: Cinclus Pharma (Q4 Review): Phase III advancing on time

Cinclus Pharma, Audiocast, Q4'25

Webcast2/18/2026, 9:00 AM

Cinclus Pharma, Audiocast, Q4'25

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release2/18/2026, 7:00 AM

Year-end report – Advancing toward Phase III readout

Press release2/13/2026, 7:00 AM

Cinclus Pharma receives positive assessment of its nonclinical development plan from the FDA

Press release2/10/2026, 7:00 AM

Cinclus Pharma receives regulatory support – EMA provides positive feedback on CMC for linaprazan glurate

Press release2/4/2026, 7:00 AM

Invitation to presentation of Cinclus Pharma’s fourth quarter report 2025

Regulatory press release1/19/2026, 4:10 PM

Resolutions at the Extraordinary General Meeting in Cinclus Pharma Holding AB (publ) on 19 January 2026

Regulatory press release12/8/2025, 7:00 AM

Cinclus Pharma’s linaprazan glurate earns China’s National Reimbursement Listing and is set to launch in China in 2026

Regulatory press release12/8/2025, 6:30 AM

Cinclus Pharma recruits Magnus Christensen as new CFO

Regulatory press release12/8/2025, 6:00 AM

Notice of Extraordinary General Meeting in Cinclus Pharma Holding AB (publ)

Regulatory press release12/1/2025, 2:25 PM

Cinclus Pharma’s Nomination Committee proposes new representative for the company’s founders to the Board

Press release11/26/2025, 7:00 AM

Cinclus Pharma invites to KOL event: insights on clinical practice for erosive Gastroesophageal Reflux Disease (GERD) patients

Press release11/20/2025, 2:19 PM

Redeye: Cinclus Pharma (Q3 review) - Pivotal studies underway

Cinclus Pharma, Audiocast, Q3'25

Webcast11/20/2025, 9:00 AM

Cinclus Pharma, Audiocast, Q3'25

Regulatory press release11/20/2025, 7:00 AM

A positive start to the Phase III study

Regulatory press release11/20/2025, 7:00 AM

A positive start to the Phase III study

Regulatory press release11/18/2025, 7:00 AM

Cinclus Pharma's Nomination Committee for the 2026 Annual General Meeting appointed

Press release11/10/2025, 7:00 AM

Cinclus Pharma sponsors a scientific conference abstract highlighting the significant clinical and economic costs of PPI treatment failures in severe erosive GERD

Press release11/5/2025, 7:00 AM

Invitation to presentation of Cinclus Pharma’s third quarter report 2025

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.